Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
Toorop AA, van Lierop ZY, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Wessels MH, Boonkamp L, Strijbis EM, van Oosten BW, De Jong BA, Lissenberg-Witte BI, Barkhof F, Moraal B, Teunissen CE, Rispens T, Uitdehaag BM, Killestein J, van Kempen ZL. Toorop AA, et al. Among authors: van dijk gw. J Neurol Neurosurg Psychiatry. 2024 Apr 12;95(5):392-400. doi: 10.1136/jnnp-2023-332119. J Neurol Neurosurg Psychiatry. 2024. PMID: 37963723 Clinical Trial.
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, Leonhard SE, Verboon C, Huizinga R, Drenthen J, Arends S, Budde IK, Kleyweg RP, Kuitwaard K, van der Meulen MFG, Samijn JPA, Vermeij FH, Kuks JBM, van Dijk GW, Wirtz PW, Eftimov F, van der Kooi AJ, Garssen MPJ, Gijsbers CJ, de Rijk MC, Visser LH, Blom RJ, Linssen WHJP, van der Kooi EL, Verschuuren JJGM, van Koningsveld R, Dieks RJG, Gilhuis HJ, Jellema K, van der Ree TC, Bienfait HME, Faber CG, Lovenich H, van Engelen BGM, Groen RJ, Merkies ISJ, van Oosten BW, van der Pol WL, van der Meulen WDM, Badrising UA, Stevens M, Breukelman AJ, Zwetsloot CP, van der Graaff MM, Wohlgemuth M, Hughes RAC, Cornblath DR, van Doorn PA; Dutch GBS Study Group. Walgaard C, et al. Among authors: van der pol wl, van dijk gw, van der ree tc, van der meulen wdm, van den berg b, van der kooi el, van der meulen mfg, van der kooi aj, van der graaff mm, van engelen bgm, van oosten bw, van koningsveld r, van doorn pa. Lancet Neurol. 2021 Apr;20(4):275-283. doi: 10.1016/S1474-4422(20)30494-4. Epub 2021 Mar 17. Lancet Neurol. 2021. PMID: 33743237 Clinical Trial.
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
Toorop AA, van Kempen ZLE, Steenhuis M, Nielsen J, Sinnige LGF, van Dijk G, Roosendaal CM, Arnoldus EPJ, Hoitsma E, Lissenberg-Witte BI, de Jong BA, Oosten BWV, Strijbis EMM, Uitdehaag BMJ, Rispens T, Killestein J; NEXT-MS study group. Toorop AA, et al. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):482-486. doi: 10.1136/jnnp-2022-330467. Epub 2023 Jan 13. J Neurol Neurosurg Psychiatry. 2023. PMID: 36639226
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
Toorop AA, Wessels MHJ, Gelissen LMY, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert JP, Wokke BHA, Kalkers NF, Hoogervorst ELJ, van Eijk JJJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, van Dijk GW, Bouvy WH, Strijbis EMM, van Oosten BW, de Jong BA, Lissenberg-Witte BI, Rispens T, Uitdehaag BMJ, Killestein J, van Kempen ZLE. Toorop AA, et al. Among authors: van dijk gw. J Neurol Sci. 2024 Jul 15;462:123102. doi: 10.1016/j.jns.2024.123102. Epub 2024 Jun 22. J Neurol Sci. 2024. PMID: 38925067 Free article. Clinical Trial.
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Toorop AA, Wessels MH, Boonkamp L, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Strijbis EM, van Oosten BW, de Jong BA, Uitdehaag BM, Rispens T, Killestein J, van Kempen ZL, Teunissen CE. Toorop AA, et al. Among authors: van dijk gw. Mult Scler. 2024 Nov;30(13):1683-1688. doi: 10.1177/13524585241293940. Epub 2024 Nov 4. Mult Scler. 2024. PMID: 39494701 Free PMC article.
Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barré syndrome.
Luijten LWG, Doets AY, Arends S, Dimachkie MM, Gorson KC, Islam B, Kolb NA, Kusunoki S, Papri N, Waheed W, Walgaard C, Yamagishi Y, Lingsma H, Jacobs BC; IGOS Consortium. Luijten LWG, et al. J Neurol Neurosurg Psychiatry. 2023 Apr;94(4):300-308. doi: 10.1136/jnnp-2022-329937. Epub 2022 Nov 25. J Neurol Neurosurg Psychiatry. 2023. PMID: 36428088
Risk Factors and Causes of Ischemic Stroke in 1322 Young Adults.
Ekker MS, Verhoeven JI, Schellekens MMI, Boot EM, van Alebeek ME, Brouwers PJAM, Arntz RM, van Dijk GW, Gons RAR, van Uden IWM, den Heijer T, de Kort PLM, de Laat KF, van Norden AGW, Vermeer SE, van Zagten MSG, van Oostenbrugge RJ, Wermer MJH, Nederkoorn PJ, Zonneveld TP, Kerkhoff H, Rooyer FA, van Rooij FG, van den Wijngaard IR, Klijn CJM, Tuladhar AM, de Leeuw FE. Ekker MS, et al. Among authors: van uden iwm, van alebeek me, van dijk gw, van zagten msg, van norden agw, van oostenbrugge rj, van rooij fg, van den wijngaard ir. Stroke. 2023 Feb;54(2):439-447. doi: 10.1161/STROKEAHA.122.040524. Epub 2022 Dec 13. Stroke. 2023. PMID: 36511150 Free PMC article.
Short-Term and Long-Term Risk of Recurrent Vascular Event by Cause After Ischemic Stroke in Young Adults.
Verburgt E, Hilkens NA, Ekker MS, Schellekens MMI, Boot EM, Immens MHM, van Alebeek ME, Brouwers PJAM, Arntz RM, van Dijk GW, Gons RAR, van Uden IWM, den Heijer T, van Tuijl JH, de Laat KF, van Norden AGW, Vermeer SE, van Zagten MSG, van Oostenbrugge RJ, Wermer MJH, Nederkoorn PJ, Kerkhoff H, Rooyer FA, van Rooij FG, van den Wijngaard IR, Ten Cate TJF, Tuladhar AM, de Leeuw FE, Verhoeven JI. Verburgt E, et al. Among authors: van dijk gw. JAMA Netw Open. 2024 Feb 5;7(2):e240054. doi: 10.1001/jamanetworkopen.2024.0054. JAMA Netw Open. 2024. PMID: 38376841 Free PMC article.
Subacute cognitive impairment after first-ever transient ischemic attack or ischemic stroke in young adults: The ODYSSEY study.
Schellekens MM, Boot EM, Verhoeven JI, Ekker MS, van Alebeek ME, Brouwers PJ, Arntz RM, van Dijk GW, Gons RA, van Uden IW, den Heijer T, de Kort PL, de Laat KF, van Norden A, Vermeer SE, van Zagten MS, van Oostenbrugge RJ, Wermer MJ, Nederkoorn PJ, van Rooij FG, van den Wijngaard IR, de Leeuw FE, Kessels RP, Tuladhar AM. Schellekens MM, et al. Among authors: van dijk gw. Eur Stroke J. 2023 Mar;8(1):283-293. doi: 10.1177/23969873221132032. Epub 2022 Oct 31. Eur Stroke J. 2023. PMID: 37021157 Free PMC article.
67 results